ClinicalTrials.gg
RecruitingNCT06927076DMT4DUpdated Apr 2, 2026

Antidepressant Response of DMT Masked With Propofol

An interventional study of N,N-Dimethyltryptamine and Placebo in Major Depressive Disorder and Psychedelic Experiences, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Depressive Disorder, Major with a site in Switzerland — 7 open to participants now, 8 under way, none of them phase 3. Depressive Disorder, Major · Switzerland.

Planned enrollment
10th of 25
112 · median 60
Started
2025
with 3 others
No phase
18 of 30
6 open now
Registered
26th of 30
by date
Lead sponsor
2 of 30
University Hospital, Basel, Switzerland

Among the 30 studies in Depressive Disorder, Major with a site in Switzerland, this one is the 10th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2025, is one of 18 with no phase, and was the 26th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

7 of the 30 studies in Depressive Disorder, Major with a site in Switzerland are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Depressive Disorder, Major with a site in Switzerland, or all of them as a file.
02

Study summary

The aim of this study is to elucidate if the anti-depressive effect of N,N-dimethyltryptamine (DMT) is based on a biological mechanisms including neuroplasticity and anti-inflammatory effect or due to the subjective psychedelic experience.

Read the detailed description

Major depressive disorder (MDD) affects nearly 20% of people, but current treatments-both pharmacological and psychotherapeutic-have limited efficacy, especially for mild to severe cases. Psychedelics like LSD, psilocybin, and DMT are being explored as alternative therapies, with studies showing promising antidepressant effects. However, it is unclear whether these benefits stem from their acute subjective (psychedelic) experience or from biological mechanisms like neuroplasticity and anti-inflammatory effects.

This study aims to determine if the antidepressant effects of DMT occur independently of its psychedelic experience. To test this, DMT will be administered under sedation (with propofol) to mask subjective effects, as well as without sedation.

03

Conditions studied

  • Major Depressive Disorder
  • Psychedelic Experiences

Keywords

  • N,N-dimethyltryptamine (DMT)
  • neuroplasticity
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must meet criteria for MDD of at least moderate severity (MADRS≥20).
  2. Participants either currently do not use antidepressants or are treated with a stable dose for at least 4 weeks prior to randomization.
  3. Age ≥ 21 years old.
  4. Sufficient understanding of the German language.
  5. Able to understand the study procedures and risks and willing to adhere to the protocol and sign the consent form.
  6. Willing not to drive or operate heavy machinery on the treatment day.
  7. Willing to refrain from more than 7 standard alcoholic drinks a week, more than 10 cigarettes a day, more than 2 cups of coffee a day, and any illicit substances during study participation.
  8. Willing to use effective measures throughout study participation.

Exclusion criteria

Exclusion Criteria:

  1. Past or present bipolar or psychotic disorder, including depressive disorder with psychotic features.
  2. First-degree relative with a psychotic or bipolar disorder.
  3. Significant prodromal psychotic symptoms (Prodromal Questionnaire-16 symptoms ≥ 6).
  4. Psychiatric condition judged to be incompatible with establishment of rapport with study team members and/or safe exposure to DMT, e.g. diagnosed or suspected borderline personality disorder.
  5. Current post-traumatic stress disorder or acute stress reaction due to a traumatic event.
  6. Post-partum depression.
  7. Pregnant or breastfeeding women.
  8. Current or recent history of significant suicide ideation or suicide behavior within the past 6 months.
  9. Current severe substance use disorder other than nicotine.
  10. Planned ketamine, other psychedelic, or electroconvulsive treatment or any such treatment within the past 3 months.
  11. Any lifetime use of DMT, use of any other psychedelics within last 3 month or lifetime use of any other psychedelics more than 15 times.
  12. Patients who are treated with neuroleptics or known antagonists of 5-HT2 receptors or monoamine oxidase inhibitors (MAOI) and are not able/willing to pause.
  13. Increased risk for adverse reactions to propofol or soja products.
  14. Increased risk for aspiration.
  15. Increased risk for difficult mask ventilation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    DMT without sedation

    DMT without sedation (propofol)

    Drug: N,N-Dimethyltryptamine · Procedure: no sedation

  • Experimental
    DMT with sedation

    DMT with sedation (propofol)

    Drug: N,N-Dimethyltryptamine · Procedure: Propofol

  • Placebo comparator
    Placebo without sedation

    Placebo (double-blind) without sedation (propofol)

    Drug: Placebo · Procedure: no sedation

  • Placebo comparator
    Placebo with sedation

    Placebo (double-blind) with sedation (propofol)

    Drug: Placebo · Procedure: Propofol

Interventions

  • administration of a 2mg/min DMT perfusion over 20 min

    Also known as: DMT

  • DrugPlacebo

    administration of a placebo perfusion over 20 min

  • ProcedurePropofol

    30 min propofol sedation

  • Procedureno sedation

    no sedation

06

What researchers measure

Primary outcomes

  1. long term changes in depressive symptoms (MADRS)

    Changes in depressive symptoms will be assessed using Montgomery-Asberg-Depression Rating Scale (MADRS). The MADRS is a ten-item questionnaire widely used to measure severity of depressive symptoms during the last week. Total score (range 0-60); higher scores indicate greater depression severity.

    Time frame: baseline (before intervention) and on day 14 post-intervention

Secondary outcomes

  1. Short term changes in depressive symptoms (MADRS)

    Changes in depressive symptoms will be assessed using Montgomery-Asberg-Depression Rating Scale (MADRS). The MADRS is a ten-item questionnaire widely used to measure severity of depressive symptoms during the last week. Total score (range 0-60); higher scores indicate greater depression severity.

    Time frame: Baseline (before intervention) and on day 1, 3 and 7 post-intervention

  2. Changes in depressive symptoms (BDI)

    Changes in depressive symptoms will be assessed using Beck Depression Inventory (BDI) questionnaire. Total score (range 0-63); higher scores indicate more severe depressive symptoms.

    Time frame: Baseline (before intervention) and on day 1, 3, 7 and 14 post-intervention

  3. Changes in anxiety (STAI)

    Changes in anxiety will be assessed using the self-reported State-Trait Anxiety Inventory (STAI) questionnaire. Separate total scores for State Anxiety (S-Anxiety) and Trait Anxiety (T-Anxiety) (each range 20-80); higher scores indicate greater anxiety.

    Time frame: Baseline (before intervention) and on day 1, 3, 7 and 14 post-intervention

  4. Changes of clinical global impression (CGI-S)

    The clinical global impression (CGI) is an instrument for the assessment of the patient's overall functioning both before and after starting the treatment. Severity of Illness (CGI-S): Rated on a 7-point scale (1 = normal, 7 = among the most extremely ill).

    Time frame: Baseline (before intervention) and on day 1, 3, 7 and 14 post-intervention

  5. Changes of clinical global impression (CGI-I)

    The clinical global impression (CGI) is an instrument for the assessment of the patient's overall functioning both before and after starting the treatment. Improvement (CGI-I): Rated on a 7-point scale (1 = very much improved, 7 = very much worse).

    Time frame: Baseline (before intervention) and on day 1, 3, 7 and 14 post-intervention

  6. Changes in quality of life (WHOQOL-bref)

    Changes in quality of life will be assessed by World Health Organization Quality of life scale (WHOQOL-bref). The WHOQOL-bref is one of the most commonly used self-rating instruments for the assessment of the quality of life and covers different domains of quality of life (physical, psychological, level of independence, social relationships, and environment, and spirituality). Domain scores (Physical, Psychological, Social, Environmental), scaled from 0 to 100; higher scores indicate better quality of life.

    Time frame: Baseline (before intervention) and on day 1, 3, 7 and 14 post-intervention

  7. Persisting positive and negative effects (PEQ)

    Psychedelics have been shown to produce persisting effects on well-being and appreciation of social relationships on the PEQ.This questionnaire will be used at the EOS visit to assess similar persisting effects of the DMT experience in addition to any effects on depressive symptomatology. Subscale scores (e.g., positive attitudes, mood changes, spirituality), typically rated 0-5 or 0-6; higher scores indicate stronger persisting effects.

    Time frame: On day 14 post-intervention

  8. Acute subjective effects (5D-ASC)

    The 5 Dimensions of Altered States of Consciousness (5D-ASC) Scale is a questionnaire containing visual analog scales for 94 items. The instrument contains five scales assessing mood, anxiety, derealization, depersonalization, changes in perception, auditory alterations, and reduced vigilance. Each item of the scale is scored on a 0-100 mm VAS. Scores for 5 dimensions (e.g., Oceanic Boundlessness, Anxious Ego Dissolution), range typically 0-100%; higher scores indicate more intense altered states.

    Time frame: On day 0 post-intervention

  9. Subjective Effects Rating (SES)

    Participants will be asked by the investigator to repeatedly rate their subjective effects verbally on a Likert scale from 0 to 10 for: "any drug effect", "good drug effect", "bad drug effect", and "fear". Ratings will be performed before and repeatedly after substance administration and will take approximately 30 sec to complete. The time course and maximal ratings (Emax, 0-10) are defined for each rating and Emax values compared between treatments using analysis of variance (ANOVAs). Total and subscale scores (range and subscales vary by implementation); higher scores indicate more intense subjective effects.

    Time frame: On day 0 pre- and post-intervention

  10. Psychedelic Experience Scale (PES)

    In the PES, 100-items are rated on a six-point scale. The PES represents a revalidation of the original 100-item States of Consciousness Questionnaire (SOCQ)

    Time frame: On day 0 post-intervention

  11. Emotional breakthrough inventory (EBI)

    The Emotional breakthrough inventory (EBI) is a validated instrument with 6 items to assess the degree of emotional breakthrough as a distinct component of the acute psychedelic experience. Total score (range varies); higher scores indicate stronger emotional breakthrough experiences.

    Time frame: On day 0 post-intervention

  12. Acute adverse effects

    Acute adverse effects wil be assessed by the List of complaints (LC). LC is a self-reporting tool to assess physical and general discomfort. A revised version is used which consists of a 40-item list covering a wide variety of symptoms and complaints that are answered with a four-point intensity-scoring ranging from "not at all" to "strong". Total number or severity of reported somatic and psychological complaints will be evaluated.

    Time frame: On day 0 and 1 post-intervention

  13. Safety events

    Adverse events will be assessed over the whole study period.

    Time frame: From day 0 to day 14 post-intervention

  14. Neuroplasticity

    brain-derived neurotrophic factor (BDNF), a biomarker for neurogenesis will be quantified in blood samples collected before and 14 days after intervention

    Time frame: Baseline (before intervention) and on day 14 post-intervention

  15. Inflammation

    Interleukin-1 beta (IL-1β) an immunological factor linked to depression will be quantified in blood samples collected before and 14 days after intervention

    Time frame: Baseline (before intervention) and on day 14 post-intervention

  16. DMT plasma concentration

    Plasma levels of DMT will be measured once shortly before the end of the perfusion

    Time frame: On day 0 shortly before the end of the perfusion

  17. Expectancy (CEQ)

    Expectancy will be assessed before the first drug administration. Thus, patients will know at this timepoint whether they get the treatment with or without propofol. To measure expectancy, a modified 2-item version of the Credibility / Expectancy Questionnaire (CEQ) is used. Credibility score (range 3-27).

    Time frame: At Baseline before intervention

  18. Expectancy

    The Stanford Expectations of Treatment Scale (SETS) will evaluate positive and negative expectancies. Expectancy score (range 3-27 or expressed as a probability %).

    Time frame: At Baseline before intervention

  19. Mood

    The Adjective Mood Rating Scale (AMRS) is a self-rating scale assessing current mood states. The AMRS will be used to assess mood before the DMT experience. Positive mood and greater acute well-being is expected to positively enhance the acute DMT effects as similarly shown for other psychedelics. Scores for multiple mood dimensions (e.g., energy, mood, agitation); higher scores reflect greater expression of that dimension.

    Time frame: At day 0 directly before administration of the study drug

  20. Personality (NEO-FFI)

    Personality traits are known to affect subjective responses to psychoactive substances. The NEO Five Factor Inventory (NEO-FFI) will be used during screening to self-assess personality traits. Scores for five domains (Neuroticism, Extraversion, Openness, Agreeableness, Conscientiousness); raw or standardized T-scores.

    Time frame: At Baseline before intervention

  21. Personality (TAS)

    Personality traits are known to affect subjective responses to psychoactive substances. The Tellegen Absorption Scale (TAS) will be used during screening to self-assess personality traits. Total score (range 0-34 or 0-136, depending on version); higher scores indicate greater trait absorption.

    Time frame: At Baseline before intervention

  22. Sedation Level (RASS)

    Level of sedation will be assessed during propofol session after each administration using the validated Richmond Agitation-Sedation Scale (RASS). The RASS is an observer-rated clinical scale used to assess level of agitation and sedation in the intensive care unit. The scale ranges from "+4" (combative) through "0" (alert and calm) to "-5" (unarousable). Intermediate scores include "+3" (very agitation), "+2" (agitated), "+1" (restless), "-1" (drowsy), "-2" (light sedation), "-3" (moderate sedation), and "-4" (deep sedation).

    Time frame: On day 0 during intervention

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Mar 2029, 43 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 43 months is above that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
Apr 15, 2025
StartActual
Aug 5, 2025
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06927076
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Aug 5, 2025
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Apr 2, 2026

Study contacts

Joyce Santos de Jesus
Contact
DMT4D@usb.ch
+41 61 556 65 02
Matthias Liechti, Prof. Dr. med.
study director · University Hospital, Basel, Switzerland
Felix Müller, PD Dr. med.
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N,N-Dimethyltryptamine

Start the discussion